A 4-week Pilot Study With the Cannabinoid Receptor Agonist Dronabinol and Its Effect on Metabolic Parameters in a Randomized Trial

Reichenbach, Zachary Wilmer; Sloan, Joshua A.; Rizvi-Toner, Amna; Bayman, Levent; Valestin, Jessica; Schey, Ron

doi:10.1016/j.clinthera.2015.07.023

Cited by 9 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two experimental studies (high ROB) examined the effect of cannabis-related compounds on metabolic factors (29, 30). Both had small sample sizes, and neither identified a measurable effect on metabolic parameters.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes

et al. 2018

View full text Add to dashboard Cite

Background: Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. Purpose: To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. Data Sources: PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between 1 January 1975 and 30 September 2017. Study Selection: Observational studies that were published in English, enrolled adults using any form of marijuana, and reported on vascular risk factors (hyperglycemia, diabetes, dyslipidemia, and obesity) or on outcomes (stroke, myocardial infarction, cardiovascular mortality, and all-cause mortality in cardiovascular cohorts). Data Extraction: Study characteristics and quality were assessed by 4 reviewers independently; strength of evidence for each outcome was graded by consensus. Data Synthesis: 13 and 11 studies examined associations between marijuana use and cardiovascular risk factors and clinical outcomes, respectively. Although 6 studies suggested a meta bolic benefit from marijuana use, they were based on cross-sectional designs and were not supported by prospective studies. Evidence examining the effect of marijuana on diabetes, dyslipidemia, acute myocardial infarction, stroke, or cardiovascular and all-cause mortality was insufficient. Although the current literature includes several long-term prospective studies, they are limited by recall bias, inadequate exposure assessment, minimal marijuana exposure, and a predominance of low-risk cohorts. Limitation: Poor- or moderate-quality data, inadequate assessment of marijuana exposure and minimal exposure in the populations studied, and variation in study design. Conclusion: Evidence examining the effect of marijuana on cardiovascular risk factors and outcomes, including stroke and myocardial infarction, is insufficient. Primary Funding Source: National Heart, Lung, and Blood Institute. (PROSPERO: CRD42016051297)

show abstract

Section: Resultsmentioning

confidence: 99%

“…In a small double-blind placebo-controlled randomized trial (high ROB), the effect of 5 mg of dronabinol on BMI was assessed at 28 days in 13 of the 19 participants who completed follow-up (30). No statistically significant association was found between marijuana use and BMI.…”

Section: Resultsmentioning

confidence: 99%

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Amongst the study completers, there were no significant changes in bodyweight nor any significant changes in metabolic parameters including cholesterol, triglycerides, glucose, insulin, and leptin. These findings indicate a lack of harmful metabolic side effects resulting from this appetite stimulating agent and warrant its potential use in patients with metabolic disorders [ 158 ]. Most recently, the efficacy and safety of dronabinol was tested in an inpatient clinical setting to assess its treatment of dampened appetite and bodyweight resulting from acute or chronic illness.…”

Section: Exploring the Direct Effects Of Cannabinoid Drugs On Bodymentioning

confidence: 99%

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

Murphy

Foll

2020

Biomolecules

View full text Add to dashboard Cite

Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight. Rimonabant, an inverse agonist for the cannabinoid CB1 receptor, was effective at producing weight loss in obese subjects. However, due to adverse psychiatric side effects, rimonabant was removed from the market. More recently, we reported an inverse relationship between cannabis use and BMI, which has now been duplicated by several groups. As those results may appear contradictory, we review here preclinical and clinical studies that have studied the impact on body weight of various cannabinoid CB1 drugs. Notably, we will review the impact of CB1 inverse agonists, agonists, partial agonists, and neutral antagonists. Those findings clearly point out the cannabinoid CB1 as a potential effective target for the treatment of obesity. Recent preclinical studies suggest that ligands targeting the CB1 may retain the therapeutic potential of rimonabant without the negative side effect profile. Such approaches should be tested in clinical trials for validation.

show abstract

“…CBD and THCV had significant positive effect compared to placebo on reduction of fasting plasma glucose, pancreatic β‐cell function, adiponectin and apolipoprotein A, but dronabinol had no clinically meaningful metabolic effect. The sample size in these studies was relatively small: 13 to 130 subjects . The therapeutic effects of cannabinoids, specifically cannabidiol (CBD), on epilepsy, mainly in young adults and children, were investigated in three trials .…”

mentioning

confidence: 99%

Medical cannabis: aligning use to evidence‐based medicine approach

Schleider

Abuhasira

Novack

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

During the past decade we have been witnessing a rise in medical cannabis use, yet the evidence for the safety and efficacy of the various cannabinoid compounds is scarce. The State of Israel has always been at the forefront of clinical and translational research in support of Evidence Based Medicine. With respect to cannabis Israel has created a medical and regulatory environment that enables clinical studies with cannabis which may lead to improved Evidence Based use of these compounds. This opinion paper discusses selected studies into the safety and effects of cannabis derived products.

show abstract

A 4-week Pilot Study With the Cannabinoid Receptor Agonist Dronabinol and Its Effect on Metabolic Parameters in a Randomized Trial

Cited by 9 publications

References 38 publications

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

Medical cannabis: aligning use to evidence‐based medicine approach

Contact Info

Product

Resources

About